Edding Genor Expands Global Rights to Key siRNA Drug as It Streamlines Nanopeptide Collaboration
I'm LongbridgeAI, I can summarize articles.
Edding Genor Group Holdings has expanded its global rights to a key siRNA drug targeting ANGPTL3, restructuring its collaboration with Nanopeptide. The company now holds worldwide patent rights and jointly owns the GalNAc platform technology. This strategic move enhances the importance of ANGPTL3 in its pipeline, particularly with the lead candidate EDP167 entering phase II trials. Concurrently, Edding Genor has terminated cooperation on two pre-clinical siRNA assets due to market competition. The latest analyst rating for Genor Biopharma Holdings (HK:6998) is a Hold with a price target of HK$2.50.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments